All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Eli Lilly, XtalPi expand AI partnership to bispecific antibodies, $345M potential deal value
Research collaboration, AI/ML, bispecific antibodies, milestone payments - Read more

Dynavax, Vaxart partner on oral COVID-19 vaccine, $25M upfront plus $5M equity investment
Licensing deal, infectious disease, vaccine, milestone payments, equity investment - Read more

Kelonia Therapeutics, Johnson & Johnson collaborate on in vivo CAR-T therapies using iGPS platform
Research collaboration, cell therapy, gene therapy, oncology - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

AstraZeneca's Imfinzi (durvalumab) reduces death risk by 22% in Ph3 gastric and gastroesophageal junction cancer trial
Antibody, cancer, monoclonal antibody, gastric cancer, perioperative therapy, combination therapy - Read more

Novo Nordisk presents Ph3 data showing oral Wegovy (semaglutide) reduces cardiovascular risk factors in obesity
Small molecule, metabolic, GLP-1 receptor agonist, obesity, cardiovascular risk factors - Read more

Centessa's ORX750 orexin receptor 2 agonist shows promise in Ph2a narcolepsy and idiopathic hypersomnia trial
Small molecule, neurological, orexin receptor agonist, narcolepsy, sleep disorders - Read more

THE GOOD
Company Launches

Braveheart Bio launches with $185M to take on Bristol Myers Squibb’s heart drug in hypertrophic cardiomyopathy
Cardiovascular, small molecule, clinical-stage, hypertrophic cardiomyopathy - Read more

THE GOOD
Earning & Finances

Amgen touts booming biosimilars sales, says U.S. market thriving amid FDA, RFK Jr. push to ease approval standards
Biosimilar, cardiovascular, strategic, financial - Read more

Madrigal Pharmaceuticals' Rezdiffra MASH treatment hits $287M Q3 sales, welcomes Novo's Wegovy competition
Small molecule, metabolic disease, competitive, revenue impact - Read more

Teva Pharmaceuticals reports 11th consecutive quarterly growth driven by innovative drug portfolio generating $830M sales
Small molecule, neurological, strategic, revenue impact - Read more

THE GOOD
Fundraises

Evommune raises $150M IPO, developing drugs for immune conditions like hives and dermatitis
Autoimmune, small molecule, dermatology, clinical-stage - Read more

LambdaVision raises $7M Seed funding for protein-based artificial retina development
Retinal disease, protein-based therapy, microgravity manufacturing, preclinical - Read more

Hepta Bio raises $6.7M seed funding for blood-based liver disease diagnostics
Liver disease, blood-based diagnostics, biomarker discovery, MASH - Read more [Paywall]

MoonLake raises $75M follow-on funding, advancing sonelokimab for inflammatory diseases
Autoimmune, antibody, inflammatory diseases, clinical-stage - Read more

THE GOOD
Investments

AstraZeneca invests additional $136M in Chinese inhalants plant, bringing total Qingdao investment to $886M
Inhalants, respiratory disease, strategic, major transaction, operational - Read more

THE GOOD
Strategic Plans

Amgen advances MariTide to Phase III obesity trials amid Pfizer-Novo bidding war for Metsera
Antibody-peptide conjugate, obesity, strategic, competitive - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Approvals & Labels

FDA rejects Biohaven's troriluzole (glutamate modulator) for spinocerebellar ataxia, company cuts R&D spending 60%
Small molecule, neurological, glutamate modulator, spinocerebellar ataxia - Read more

THE BAD
Clinical Trials

Amgen halts bemarituzumab Ph1b/3 trial for advanced gastric cancer due to inadequate efficacy
Antibody, cancer, monoclonal antibody, gastric cancer, FGFR2b target, combination therapy - Read more

THE BAD
Earnings & Finances

Novo Nordisk CEO calls diabetes-obesity turnaround a 'marathon' after disappointing Q3 earnings performance
GLP-1 agonist, diabetes, obesity, financial, competitive, strategic - Read more

Charles River cuts costs, divests 7% of business amid continued revenue decline
CRO services, strategic, cost reduction, operational - Read more

THE BAD
Layoffs

Novo Nordisk abandons oncology, early MASH programs in $1.4B restructuring cutting 9,000 jobs
Cell therapy, oncology, strategic, cost reduction, operational - Read more

THE BAD
Mergers & Acquisitions

FTC warns Novo Nordisk's Metsera acquisition bid may circumvent required antitrust premarket review process
GLP-1 agonist, obesity, strategic, major transaction, competitive, regulatory - Read more

Delaware judge denies Pfizer's request to block Novo Nordisk's competing bid for Metsera biotech
Obesity therapeutics, strategic, major transaction, competitive - Read more

THE BAD
Strategic Plans

Supernus pauses new Parkinson's pump Onapgo patient starts due to overwhelming demand, supplier constraints
Small molecule, neurological, operational, supply chain - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here